Clinical trials
1 active trial in India
Recruiting, about to start, or running now.
- Effect of Weight Loss From ESG Plus Lifestyle Changes vs. Lifestyle Changes Alone in Sleep Apnea Patients NCT07082608
Updated
Reviewed by Chandani Patel
India Endoscopic Bariatric Therapies Market Industry Trends and Forecast to 2034: Segmented by (Procedure, Product, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$38.3 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $13.5 Mn | — | — |
| 2025 (base) | $15.6 Mn | +$2.0 Mn | — |
| 2026 (forecast) | $17.9 Mn | +$2.3 Mn | +14.8% |
| 2027 (forecast) | $20.5 Mn | +$2.6 Mn | +31.8% |
| 2028 (forecast) | $23.5 Mn | +$3.0 Mn | +51.3% |
| 2029 (forecast) | $27.0 Mn | +$3.5 Mn | +73.7% |
| 2030 (forecast) | $31.0 Mn | +$4.0 Mn | +99.4% |
| 2031 (forecast) | $35.6 Mn | +$4.6 Mn | +128.9% |
| 2032 (forecast) | $40.9 Mn | +$5.3 Mn | +162.8% |
| 2033 (forecast) | $46.9 Mn | +$6.0 Mn | +201.7% |
| 2034 (forecast) | $53.9 Mn | +$6.9 Mn | +246.3% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $15.6 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $53.9 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 14.8% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Procedure, product and end user (see all) |
| Key players | Boston Scientific Corporation, Apollo Endosurgery, Fractyl Health, GI Dynamics, Olympus Corporation (see all) |
| Regulator in India | CDSCOSource: Central Drugs Standard Control Organisation. Checked 14 Nov 2026. |
| Active clinical trials | 1 in IndiaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in India. Retrieved 12 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Endoscopic bariatric therapies are weight-loss procedures done through the mouth with a flexible scope, without cuts in the skin.
Key segments of the endoscopic Bariatric Therapies market include procedure (Endoscopic Sleeve Gastroplasty, Intragastric Balloon and Duodenal Mucosal Resurfacing) and product (Suturing Systems, Balloons and Liners).
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the endoscopic Bariatric Therapies market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.
Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the endoscopic Bariatric Therapies market, especially in fast-growing emerging economies.
High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the endoscopic Bariatric Therapies market. Long-term safety data and lifestyle support are still needed for many patients.
The endoscopic Bariatric Therapies market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Since October 2023, every medical device sold in India needs a licence under the Medical Devices Rules, 2017, from the Central Drugs Standard Control Organisation (CDSCO) or, for some lower-risk devices made in India, a state authority.[1] Ayushman Bharat PM-JAY gives eligible families hospital cover of up to ₹5 lakh a year.[2] ClinicalTrials.gov lists 1 study on Endoscopic Bariatric Therapies that is recruiting, active or about to start in India.[3] Obesity (adults): 8.0% of adults in 2024, the latest WHO figure for India.[4]
[1] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.
[2] National Health Authority (PM-JAY). Checked 14 Nov 2026.
[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in India. Retrieved 12 Nov 2026.
[4] WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 22 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how endoscopic Bariatric Therapies products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in India.
What doctors and scientists are doing in Endoscopic Bariatric Therapies right now, from free public sources.
1 active trial in India
Recruiting, about to start, or running now.
8.0 % of adults
Obesity (adults), India, 2024 (WHO).
Compare every country on the Public Health DashboardSources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 22 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 21 Nov 2026.
[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 22 Nov 2026.
[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 22 Nov 2026.
From our blog
India · 1 shared keyword
India · 1 shared keyword
India · 1 shared keyword
India
India
India
Pharmaceuticals · India
Public Health · India
Pharmaceuticals · India
Healthcare Services · India
Digital Health · India
Pharmaceuticals · India